ALLOGENEIC STEM CELL TRANSPLANTATION FOR ADULT PATIENTS WITH ACUTE LEUKEMIA – 14 YEARS EXPERIENCE
Background. This study was designed to evaluate the impact of various prognostic factors on long-term survival and event free survival after allogeneic hematopoietic stem cell transplantation for patients with acute leukemia.
Methods and patients. Between years 1989 and 2002 44 patients with acute leukemia (30 with AML and 14 with ALL) were transplanted. Survival curves using the Kaplan-Meier method were calculated for patients transplanted with two different sources of stem cells – bone marrow and peripheral blood and separately for patients with female donor.
Results. Estimated 10 years survival for AML is 43% and 64% for ALL patients which is not statistically different. There are no significant differences in outcome regarding source of stem cells and in donors’ gender.
Conclusions. To conclude, our results show that neither source of stem cells nor donor’s gender has impact on the long-term survival after hematopoietic stem cell transplantation. As published previously patients transplanted beyond the first remission have significantly worse outcome.
Zittoun RA, Mandelli F, Willemze R et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995; 332: 217–23.
Pretnar J, Bohinjec M, Černelč P, Lukić L, Zwitter M. Presaditev kostnega mozga pri zdravljenju levkemij – naše prve izkušnje. Zdrav Vestn 1990; 59: 265–7.
Barret J, Childs R. Non-myeloablative stem cell transplants – annotation. British Journal of Haematology 2000; 111: 6–17.
Newland A. Progress in the treatment of acute leukemia in adults. Int J Hematol 2002; 76: 253–8.
Pretnar J, Preložnik-Zupan I. Allogeneic stem cell transplantation for patients with acute leukemia. Sixth seminar New trends in the treatment of acute leukemia. Programme and abstract book. Dubrovnik, 2001: 109–16.
Eisner MD, August CS. Impact of donor and recipient characteristics on the development of acute and chronic GVHD following pediatric bone marrow transplantation. Bone Marrow Transplant 1995; 15: 663–8.
Remberger M, Kumlien G, Aschan J et al. Risk factors for moderate-to-severe chronic GVHD after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002; 8: 674–82.
Russel JA, Larrat L, Brown C et al. Allogeneic blood stem cell and bone marrow transplantation for acute myelogenous leukemia and myelodysplasia: influence of stem cell source on outcome. Bone Marrow Transplant 1999; 24: 1177–83.
Champlin RE, Schmitz N, Horowitz M et al. Blood stem cells compared with bone marrow as source of hematopoietic cells for allogeneic transplantation. IBMTR histocompatibility and stem cell sources working committee and EBMT. Blood 2000; 95: 3702–9.
Ringden O, Labopin M, Bacigalupo A et al. Transplantation of peripheral blood stem cells as compared with marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. J Clin Oncol 2002; 20: 4655–64.
Del Canizo MC, Martinez C, Conde E et al. Peripheral blood is safer than bone marrow as source of hematopoietic progenitors in patients with myelodisplastic syndrome who receive allogeneic transplantation. Results from Spanish registry. Bone Marrow Transplant 2003; 32: 987–92.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.